Gilead Sciences’ seladelpar has been granted conditional marketing authorisation by the European Commission (EC) to treat ...

Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...

Gilead Sciences’ seladelpar has won conditional marketing authorization to treat primary biliary cholangitis (PBC) alongside ...

Bernstein raised the firm’s price target on Gilead (GILD) to $120 from $105 and keeps an Outperform rating on the shares. The firm notes Gilead ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis ...

Sciences announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...

Primary Biliary Cholangitis Clinical Trial Pipeline Pharmaceutical companies are advancing the Primary Biliary Cholangitis treatment pipeli ...

Gilead Sciences, Inc. GILD reported better-than-expected fourth-quarter results and provided an upbeat guidance for 2025.

This was primarily driven by the launch of Livdelzi® (seladelpar) in primary biliary cholangitis ("PBC"), and increased demand in products for chronic hepatitis B virus ("HBV") and chronic hepatitis ...

Gilead reports Q4 earnings on Feb. 11. Analysts expect $1.70 EPS. The LEO Pharma deal could reduce 2025 EPS by up to $0.17.

52.2% of patients met the composite endpoint of the study. Seladelpar can result in clinically meaningful improvements in markers of cholestasis and liver injury in patients with primary biliary ...

In an important regulatory win for Denmark’s Novo Nordisk (NOV: N), the US Food and Drug Administration (FDA) yesterday approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening, ...